Colorectal cancer is now the leading cause of cancer death in patients under 50 Why aren’t 45-year-olds getting their recommended CRC screenings?

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients

The incidence of multiple cancer types in people under the age of 50 has been rising, with early-onset cancers now contributing to nearly 15,000 excess cases of cancer in the U.S. annually.

March 27, 2026

Vol.52 No.12

By W. Kimryn Rathmell

Trials & Tribulations

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

March is National Colorectal Cancer Awareness Month. It is a reminder of a heartbreaking trend that oncologists like me are witnessing in our clinics: Last year, for the first time, colorectal cancer became the leading cause of cancer-related death in Americans under the age of 50, according to data published earlier this year in JAMA.

March 27, 2026

Vol.52 No.12

By Richard M. Goldberg

Early-onset colorectal cancer demands a new research playbook

Colorectal cancer is no longer a disease confined to older adults.

As more people are surviving cancer, we must continue funding bold science

The cancer research community has a reason to celebrate. For the first time, 70% of people are living at least five years beyond their cancer diagnosis. And, as importantly, cancer death rates have been dropping relentlessly—by more than a third since 1991.

Rectal cancer incidence rising after decades of decline as colorectal cancer shifts toward younger generations, ACS report finds

Colorectal cancer rates in the U.S. are moving in two very different directions, according to a report released from the American Cancer Society.

March 06, 2026

Vol.52 No.09

Drugs & Targets

FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer

FDA granted full approval to Braftovi (encorafenib) in combination with cetuximab (Erbitux) and fluorouracil-based chemotherapy for the treatment of adult patients with metastatic colorectal cancer with a BRAF V600E mutation based on results from the global phase III BREAKWATER trial.

February 27, 2026

Vol.52 No.08

Colorectal cancer is now the leading cause of cancer death in patients under 50

Why aren’t 45-year-olds getting their recommended CRC screenings?

YOU MAY BE INTERESTED IN

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt

Early-onset colorectal cancer demands a new research playbook

As more people are surviving cancer, we must continue funding bold science

Rectal cancer incidence rising after decades of decline as colorectal cancer shifts toward younger generations, ACS report finds

FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer

Renew today!

Subscriber content

Never miss an issue!

Login

Colorectal cancer is now the leading cause of cancer death in patients under 50

Why aren’t 45-year-olds getting their recommended CRC screenings?

YOU MAY BE INTERESTED IN

Early-onset cancer is on the rise. Here is how OSUCCC–James is adapting to the needs of younger patients

In the era of immunotherapy, response rate alone fails to predict true patient benefitRegulators must adapt

Early-onset colorectal cancer demands a new research playbook

As more people are surviving cancer, we must continue funding bold science

Rectal cancer incidence rising after decades of decline as colorectal cancer shifts toward younger generations, ACS report finds

FDA approves Braftovi combination regimen in first-line metastatic colorectal cancer

Never miss an issue!

Login

In the era of immunotherapy, response rate alone fails to predict true patient benefit
Regulators must adapt